利那克洛肽治疗肠易激综合征伴便秘

Future Prescriber Pub Date : 2013-01-16 DOI:10.1002/fps.98

Steve Chaplin MSc, MRPharmS

{"title":"利那克洛肽治疗肠易激综合征伴便秘","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.98","DOIUrl":null,"url":null,"abstract":"<p>Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"14-16"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.98","citationCount":"13","resultStr":"{\"title\":\"Linaclotide for irritable bowel syndrome with constipation\",\"authors\":\"Steve Chaplin MSc, MRPharmS\",\"doi\":\"10.1002/fps.98\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"13 3\",\"pages\":\"14-16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.98\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.98\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.98","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 13

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Linaclotide for irritable bowel syndrome with constipation

Linaclotide is a guanylate cyclase agonist that promotes increased stool water content, which increases bowel movement frequency. It has recently received a positive opinion from the CHMP for the treatment of constipation-predominant IBS. In this Drug profile Steve Chaplin presents the clinical data relating to its efficacy and adverse events. Copyright © 2013 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量